On November 6, 2024, bluebird bio, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders elected John O. Agwunobi, Elisabeth Leiderman, and Andrew Obenshain as Class II directors. Additionally, the stockholders approved the amendment and restatement of the 2023 Incentive Award Plan, increasing the number of shares authorized for issuance by 15 million to a total of 20.2 million. The compensation paid to the company's named executive officers was approved in a non-binding advisory vote. However, the proposal to amend the Certificate of Incorporation for officer exculpation did not receive the required votes for approval. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. A proposal to adjourn the Annual Meeting to solicit additional proxies for the approval of certain proposals was also passed. The meeting was adjourned with respect to a proposal for a reverse stock split, with the reconvened meeting scheduled for December 4, 2024.

On November 6, 2024, bluebird bio, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders elected John O. Agwunobi, Elisabeth Leiderman, and Andrew Obenshain as Class II directors. Additionally, the stockholders approved the amendment and restatement of the 2023 Incentive Award Plan, increasing the number of shares authorized for issuance by 15 million to a total of 20.2 million. The compensation paid to the company's named executive officers was approved in a non-binding advisory vote. However, the proposal to amend the Certificate of Incorporation for officer exculpation did not receive the required votes for approval. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. A proposal to adjourn the Annual Meeting to solicit additional proxies for the approval of certain proposals was also passed. The meeting was adjourned with respect to a proposal for a reverse stock split, with the reconvened meeting scheduled for December 4, 2024.